241 related articles for article (PubMed ID: 28065590)
1. Mechanism and evidence of nonsense suppression therapy for genetic eye disorders.
Richardson R; Smart M; Tracey-White D; Webster AR; Moosajee M
Exp Eye Res; 2017 Feb; 155():24-37. PubMed ID: 28065590
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders.
Asiful Islam M; Alam F; Kamal MA; Gan SH; Wong KK; Sasongko TH
Curr Pharm Des; 2017; 23(11):1598-1609. PubMed ID: 27875971
[TBL] [Abstract][Full Text] [Related]
3. Translational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations.
Nagel-Wolfrum K; Möller F; Penner I; Wolfrum U
Vis Neurosci; 2014 Sep; 31(4-5):309-16. PubMed ID: 24912600
[TBL] [Abstract][Full Text] [Related]
4. Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression.
Roy B; Friesen WJ; Tomizawa Y; Leszyk JD; Zhuo J; Johnson B; Dakka J; Trotta CR; Xue X; Mutyam V; Keeling KM; Mobley JA; Rowe SM; Bedwell DM; Welch EM; Jacobson A
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12508-12513. PubMed ID: 27702906
[TBL] [Abstract][Full Text] [Related]
5. Nonsense suppression therapies in human genetic diseases.
Martins-Dias P; Romão L
Cell Mol Life Sci; 2021 May; 78(10):4677-4701. PubMed ID: 33751142
[TBL] [Abstract][Full Text] [Related]
6. Nonsense suppression therapies in ocular genetic diseases.
Wang X; Gregory-Evans CY
Cell Mol Life Sci; 2015 May; 72(10):1931-8. PubMed ID: 25651836
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
[TBL] [Abstract][Full Text] [Related]
8. Sense from nonsense: therapies for premature stop codon diseases.
Bidou L; Allamand V; Rousset JP; Namy O
Trends Mol Med; 2012 Nov; 18(11):679-88. PubMed ID: 23083810
[TBL] [Abstract][Full Text] [Related]
9. Therapeutics based on stop codon readthrough.
Keeling KM; Xue X; Gunn G; Bedwell DM
Annu Rev Genomics Hum Genet; 2014; 15():371-94. PubMed ID: 24773318
[TBL] [Abstract][Full Text] [Related]
10. Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond.
Wagner RN; Wießner M; Friedrich A; Zandanell J; Breitenbach-Koller H; Bauer JW
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047074
[TBL] [Abstract][Full Text] [Related]
11. Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity.
Baradaran-Heravi A; Niesser J; Balgi AD; Choi K; Zimmerman C; South AP; Anderson HJ; Strynadka NC; Bally MB; Roberge M
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3479-3484. PubMed ID: 28289221
[TBL] [Abstract][Full Text] [Related]
12. Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
Keeling KM; Bedwell DM
Wiley Interdiscip Rev RNA; 2011; 2(6):837-52. PubMed ID: 21976286
[TBL] [Abstract][Full Text] [Related]
13. Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).
Nagel-Wolfrum K; Möller F; Penner I; Baasov T; Wolfrum U
BioDrugs; 2016 Apr; 30(2):49-74. PubMed ID: 26886021
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic promise of engineered nonsense suppressor tRNAs.
Porter JJ; Heil CS; Lueck JD
Wiley Interdiscip Rev RNA; 2021 Jul; 12(4):e1641. PubMed ID: 33567469
[TBL] [Abstract][Full Text] [Related]
15. Nonsense suppression by near-cognate tRNAs employs alternative base pairing at codon positions 1 and 3.
Roy B; Leszyk JD; Mangus DA; Jacobson A
Proc Natl Acad Sci U S A; 2015 Mar; 112(10):3038-43. PubMed ID: 25733896
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development.
Rowe SM; Clancy JP
BioDrugs; 2009; 23(3):165-74. PubMed ID: 19627168
[TBL] [Abstract][Full Text] [Related]
17. Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.
Bidou L; Bugaud O; Belakhov V; Baasov T; Namy O
RNA Biol; 2017 Mar; 14(3):378-388. PubMed ID: 28145797
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.
Li S; Li J; Shi W; Nie Z; Zhang S; Ma F; Hu J; Chen J; Li P; Xie X
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371567
[TBL] [Abstract][Full Text] [Related]
19. Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms.
Ng MY; Li H; Ghelfi MD; Goldman YE; Cooperman BS
Proc Natl Acad Sci U S A; 2021 Jan; 118(2):. PubMed ID: 33414181
[TBL] [Abstract][Full Text] [Related]
20. Translational Read-Through Therapy of
Vössing C; Owczarek-Lipska M; Nagel-Wolfrum K; Reiff C; Jüschke C; Neidhardt J
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
